• Anna Chapman
  • Yasser El MiedanyEmail author


Once considered to be solely a cutaneous disease, there is robust evidence that psoriasis is associated with systemic inflammation and a significantly increased risk of comorbidity. It has yet to be established whether these comorbidities occur as a direct result of the systemic inflammation associated with psoriasis, as a consequence of genetically determined selection, or whether other factors are involved. It is now well documented that patients with severe psoriasis have an excess mortality compared to the general population. Moderate to severe psoriasis is associated with a higher incidence of cardiovascular risk factors such as diabetes mellitus, obesity, smoking and metabolic syndrome. Therefore, both rheumatologists and dermatologists should be vigilant to any risk factors that might aggravate the psoriasis patient’s condition. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented to most effectively manage psoriasis patients. This chapter will give a brief background to psoriasis, pathophysiology to psoriasis-associated comorbidities and the new concept of the “psoriatic march”. It will also discuss the scientific evidence for each comorbidity, its therapeutic implications and approaches to screen and assess in standard daily practice.


Psoriasis Comorbidities of psoriasis Cardiovascular morbidity in psoriasis Arthritis Spondyloarthritis HLA-B27 


  1. 1.
    Henseler T, Christophers E. Disease concomittance in psoriasis. J Am Acad Dermatol. 1995;32(6):982–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):3–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Gottlieb AB, et al. Psoriasis comorbidities. J Dermatol Treat. 2008;19(1):5–21.CrossRefGoogle Scholar
  4. 4.
    Cohen AD, et al. Association between psoriasis and the metabolic syndrome. Dermatology. 2008;216(2):152–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Langan SM, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Neimann AL, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39(3):212–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol. 2009;129(7):1601–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Nestle FO, Kaplan DH, Barker J. NEJM. 2009;361:496–509.PubMedCrossRefGoogle Scholar
  10. 10.
    Griffiths CE, Barker JN. Lancet. 2007;370:263–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Boehncke W, Boehncke S, Tobin A, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Hukuda S, Minami M, Saito T, Mitsui H, Matsui N, Komatsubara Y, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001;28:554–9.PubMedGoogle Scholar
  13. 13.
    Ruderman EM, Tambar S. Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. Dermatol Clin. 2004;22:477–86.PubMedCrossRefGoogle Scholar
  14. 14.
    Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.PubMedCrossRefGoogle Scholar
  15. 15.
    Bennet RM. Psoriatic arthritis. In: DJ MC, editor. Arthritis and related conditions. Philadelphia: Lea & Febiger; 1979. p. 645.Google Scholar
  16. 16.
    Vasey FB, Espinoza LR. Psoriatic arthropathy. In: Calin A, editor. Spondyloarthropathies. Orlando: Grune & Stratton, Inc.; 1984. p. 151–85.Google Scholar
  17. 17.
    Fournié B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, Marc V, et al. Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Engl Ed. 1999;66:446–56.PubMedGoogle Scholar
  18. 18.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol. 1998;25:730–3.PubMedGoogle Scholar
  20. 20.
    Bowes J, Eyre S, Flynn E, Ho P, Salah S, Warren RB, et al. Evidence to support IL- 13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis. 2011;70:1016–9.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol. 2005;52:1–19. Finzi AF, Gibelli E. Psoriatic arthritis. Int J Dermatol 1991;30:1–7.Google Scholar
  22. 22.
    Zhang C, Zhu KJ, Zheng HF, Cui Y, Zhou FS, Chen YL, et al. The effect of overweight and obesity on psoriasis patients in Chinese Han population: a hospital-based study. J Eur Acad Dermatol Venereol. 2011;25:87–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–64.PubMedCrossRefGoogle Scholar
  24. 24.
    Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs. 2000;9:1511–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14–7.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Espinoza LR, Cuellar ML. Psoriatic arthritis and spondylitis: a clinical approach. In: Calin A, Taurog JD, editors. Spondylarthritides. Oxford: Oxford University Press; 1998. p. 97–111.Google Scholar
  27. 27.
    Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez LC. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991;30:245–50.PubMedCrossRefGoogle Scholar
  28. 28.
    Slobodin G, Rosner I, Rozenbaum M, Boulman N, Kessel A, Toubi E. Psoriatic arthropathy: where now? Isr Med Assoc J. 2009;11:430–4.PubMedGoogle Scholar
  29. 29.
    Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford). 2005;44:390–7.CrossRefGoogle Scholar
  31. 31.
    Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57:581–7.PubMedCrossRefGoogle Scholar
  32. 32.
    El Miedany Y, El Gaafary M, Youssef S, Palmer D. Towards a multidimensional patient reported outcome measures assessment: development and validation of a questionnaire for patients with ankylosing spondylitis/spondyloarthritis. Joint Bone Spine. 2010;77(6):575–81.PubMedCrossRefGoogle Scholar
  33. 33.
    De Simone C, Guerriero C, Giampetruzzi AR, Costantini M, Di Gregorio F, Amerio P. Achilles tendinitis in psoriasis: clinical and sonographic findings. J Am Acad Dermatol. 2003;49:217–22.PubMedCrossRefGoogle Scholar
  34. 34.
    El Miedany Y, El Gaafary M, Youssef S, Ahmed I, Nasr A. Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage. Clin Rheumatol. 2015;34(2):307–13.PubMedCrossRefGoogle Scholar
  35. 35.
    Schwenzer NF, Kötter I, Henes JC, Schraml C, Fritz J, Claussen CD, et al. The role of dynamic contrast-enhanced MRI in the differential diagnosis of psoriatic and rheumatoid arthritis. AJR Am J Roentgenol. 2010;194:715–20.PubMedCrossRefGoogle Scholar
  36. 36.
    De Oliveira M, Rocha B, Duarte G. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):09–20.CrossRefGoogle Scholar
  37. 37.
    Gladman DD, Christopher R. Clinical manifestations and diagnosis of psoriatic arthritis. [Internet]. 2010; 18.1. Available from:
  38. 38.
    Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64:ii74–7.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health. 2008;11:400–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15:i–xxi.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Queiro-Silva R, Torre-Alonso JC, Tinturé-Eguren T, López-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis. 2003;62:68–70.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40:1868–72.PubMedCrossRefGoogle Scholar
  43. 43.
    Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72:211–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636–47.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Cohen AD, et al. Psoriasis associated with ulcerative colitis and Chron’s disease. J Eur Acad Dermatol Venereol. 2009;23:561–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87–113.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet. 2008;45(2):114–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122(2):201–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128(7):1653–61.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A. Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol. 2008;27(3):377–80.PubMedCrossRefGoogle Scholar
  52. 52.
    Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J Gastroenterol. 2006;12(23):3628–35.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis. 2013;72(7):1200–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Birkenfeld S, Dreiher J, Weitzman D, Cohen AD. Coeliac disease associated with psoriasis. Br J Dermatol. 2009;161(6):1331–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924–30.PubMedCrossRefGoogle Scholar
  56. 56.
    Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli R. Another paradox in Crohn’s disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis. 2007;13(8):1059–61.PubMedCrossRefGoogle Scholar
  57. 57.
    Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis. 2007;80(3):231–7.PubMedGoogle Scholar
  58. 58.
    Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9(1):1–14.PubMedCrossRefGoogle Scholar
  59. 59.
    Aeberli D, Seitz M, Jüni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005;44(2):172–5.CrossRefGoogle Scholar
  60. 60.
    Vague J. Sexual differentiation, a factor affecting the forms of obesity. Presse Méd. 1947;30:339–40.Google Scholar
  61. 61.
    Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337–50.PubMedCrossRefGoogle Scholar
  62. 62.
    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–56.PubMedCrossRefGoogle Scholar
  63. 63.
    Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001;60(3):349–56.PubMedCrossRefGoogle Scholar
  64. 64.
    Cohen AD, et al. Psoriasis and metabolic syndrome. Acta Derm Venereol. 2007;87(6):506–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010;2010:Pii 289645–55. doi: 10.1155/2010/289645.
  66. 66.
    Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010;76(6):662–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Gisondi P, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital- based case-control study. Br J Dermatol. 2007;157(1):68–73.PubMedCrossRefGoogle Scholar
  68. 68.
    Sommer DM, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Ross R, Aru J, Freeman J, Hudson R, Janssen I. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab. 2002;282:E657–63.PubMedCrossRefGoogle Scholar
  70. 70.
    Carrascosa JM, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobaderm registry. J Eur Acad Dermatol Venereol. 2013;15 doi: 10.1111/jdv.12208.
  71. 71.
    Jensen P, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149(7):795–801.PubMedCrossRefGoogle Scholar
  72. 72.
    Herron MD, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527–34.PubMedCrossRefGoogle Scholar
  73. 73.
    Sterry W, et al. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649–55.PubMedCrossRefGoogle Scholar
  74. 74.
    Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen H-D. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol. 2008;158(5):1134–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144(12):1571–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008;159(5):1207–8.PubMedGoogle Scholar
  77. 77.
    Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010;24(12):1386–94.PubMedCrossRefGoogle Scholar
  78. 78.
    Zhu KJ, Zhang C, Li M, Zhu CY, Shi G, Fan YM. Leptin levels in patients with psoriasis: a meta-analysis. Clin Exp Dermatol. 2013;38(5):478–83.PubMedCrossRefGoogle Scholar
  79. 79.
    Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol. 2005;174(6):3137–42.PubMedCrossRefGoogle Scholar
  80. 80.
    Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105(1):31–44.PubMedCrossRefGoogle Scholar
  81. 81.
    Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Florin V, Cottencin AC, Delaporte E, Staumont-Sallé D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol. 2013;27(2):e186–90.PubMedCrossRefGoogle Scholar
  83. 83.
    Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther. 2011;24(4):446–51.PubMedCrossRefGoogle Scholar
  84. 84.
    Prignano F, Ricceri F, Pescitelli L, et al. Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin. 2009;25(9):2311–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res. 2008;57(4):290–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22(3):341–4.PubMedCrossRefGoogle Scholar
  87. 87.
    Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest. 1997;100(11):2777–82.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58(3):443–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145(4):379–82.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol. 2008;159(6):1331–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–9.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012;148(9):995–1000.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Coto-Segura P, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013; doi: 10.1111/bjd.12473.
  94. 94.
    Armstrong AW, et al. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:84–91.PubMedCrossRefGoogle Scholar
  95. 95.
    Cohen AD, et al. Psoriasis and diabetes: a population-based crosssectional study. J Eur Acad Dermatol Venereol. 2008;22:585–9.31.PubMedCrossRefGoogle Scholar
  96. 96.
    Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol. 2010;37(2):146–55.PubMedCrossRefGoogle Scholar
  97. 97.
    Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Farrokhi F, Taylor HC, McBride NM. Etanercept-induced hypoglycemia and improved glycemic control in a patient with type 2 diabetes. Endocr Pract. 2011;17(2):306–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Wambier CG, Foss-Freitas MC, Paschoal RS, et al. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol. 2009;60(5):883–5.PubMedCrossRefGoogle Scholar
  100. 100.
    Cheung D, Bryer-Ash M. Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2009;60(6):1032–6.PubMedCrossRefGoogle Scholar
  101. 101.
    Morikang E, Benson SC, Kurtz TW, Pershadsingh HA. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens. 1997;10(4 Pt 1):440–6.PubMedGoogle Scholar
  102. 102.
    Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79–82.PubMedCrossRefGoogle Scholar
  103. 103.
    Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000;136(5):609–16.PubMedCrossRefGoogle Scholar
  104. 104.
    Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med. 2012;17(6):171–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and nutrition examination survey. JAMA. 2002;287(3):356–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Lakka HM, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle- aged men. JAMA. 2002;288(21):2709–16.PubMedCrossRefGoogle Scholar
  107. 107.
    Meigs JB, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906–12.PubMedCrossRefGoogle Scholar
  108. 108.
    Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066–76.PubMedCrossRefGoogle Scholar
  109. 109.
    Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–62.PubMedCrossRefGoogle Scholar
  110. 110.
    Singh G, Aneja S. Cardiovascular comorbidity in psoriasis. Indian J Dermatol. 2011;56(5):553–6.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012;89:24–8.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1–6.CrossRefGoogle Scholar
  113. 113.
    Balta I, Balta S, Demirkol S, et al. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology. 2014;65(1):74–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008;159(Suppl 2):10–7.PubMedCrossRefGoogle Scholar
  115. 115.
    Yildiz M. Arterial distensibility in chronic inflammatory rheumatic disorders. Open Cardiovasc Med J. 2010;4:83–8.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Costa L, Caso F, D’Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31(4):711–5.PubMedCrossRefGoogle Scholar
  117. 117.
    Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol. 2004;18(2):180–3.PubMedCrossRefGoogle Scholar
  118. 118.
    Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg Cohort study, 1984 to 1992. Circulation. 1999;99(2):237–42.PubMedCrossRefGoogle Scholar
  119. 119.
    Vanizor Kural B, Orem A, Cims¸it G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta. 2003;332(1–2):23–30.PubMedCrossRefGoogle Scholar
  120. 120.
    Vanizor Kural B, Orem A, Cims¸it G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta. 2003;328(1–2):71–82.PubMedCrossRefGoogle Scholar
  121. 121.
    Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150(5):917–28.PubMedCrossRefGoogle Scholar
  122. 122.
    Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999;141(6):1054–60.PubMedCrossRefGoogle Scholar
  123. 123.
    Nofal A, Al-Makhzangy I, Attwa E, Nassar A, Abdalmoati A. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol. 2009;23(7):803–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Bhardwaj S, Roy H, Heikura T, Ylä-Herttuala S. VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur J Clin Investig. 2005;35(11):669–76.CrossRefGoogle Scholar
  125. 125.
    McDonald I, Connolly M, Tobin AM. A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. J Nutr Metab. 2012;2012:965385.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Brazzelli V, Grasso V, Fornara L, et al. Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity. Int J Immunopathol Pharmacol. 2010;23(3):911–6.PubMedCrossRefGoogle Scholar
  127. 127.
    Duell PB, Malinow MR. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol. 1997;8(1):28–34.PubMedCrossRefGoogle Scholar
  128. 128.
    El-Khairy L, Ueland PM, Refsum H, Graham IM, Vollset SE. European concerted action project. Plasma total cysteine as a risk factor for vascular disease: the European concerted action project. Circulation. 2001;103(21):2544–9.PubMedCrossRefGoogle Scholar
  129. 129.
    Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol. 2006;155(6):1165–9.PubMedCrossRefGoogle Scholar
  130. 130.
    Richetta AG, Mattozzi C, Macaluso L, et al. Homocysteine plasmatic status in patients with psoriasis. Eur J Dermatol. 2011;21(4):621–3.PubMedGoogle Scholar
  131. 131.
    Kimball AB, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med. 2010;123:350–7.PubMedCrossRefGoogle Scholar
  132. 132.
    Gelfland JM, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.CrossRefGoogle Scholar
  133. 133.
    Ahlehoff O, Gislason GH, Jørgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort study. Eur Heart J. 2012;33(16):2054–64.PubMedCrossRefGoogle Scholar
  134. 134.
    Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–67.PubMedCrossRefGoogle Scholar
  135. 135.
    Troitzsch P, Paulista Markus MR, Dörr M, et al. Psoriasis is associated with increased intima-media thickness – the Study of Health in Pomerania (SHIP). Atherosclerosis. 2012;225(2):486–90.PubMedCrossRefGoogle Scholar
  136. 136.
    Balci DD, Balci A, Karazincir S, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):1–6.PubMedCrossRefGoogle Scholar
  137. 137.
    Enany B, El Zohiery AK, Elhilaly R, Badr T. Carotid intima-media thickness and serum leptin in psoriasis. Herz. 2012;37(5):527–33.PubMedCrossRefGoogle Scholar
  138. 138.
    El-Mongy S, Fathy H, Abdelaziz A, et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol. 2010;24(6):661–6.PubMedCrossRefGoogle Scholar
  139. 139.
    Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology. 2009;218(2):110–3.PubMedCrossRefGoogle Scholar
  140. 140.
    Yiu KH, Yeung CK, Zhao CT, et al. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med. 2013;273(3):273–82.PubMedCrossRefGoogle Scholar
  141. 141.
    Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156(2):271–6.PubMedCrossRefGoogle Scholar
  142. 142.
    Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St Francis heart study. J Am Coll Cardiol. 2005;46(1):158–65.PubMedCrossRefGoogle Scholar
  143. 143.
    Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St Francis heart study randomized clinical trial. J Am Coll Cardiol. 2005;46(1):166–72.PubMedCrossRefGoogle Scholar
  144. 144.
    Osto E, Piaserico S, Maddalozzo A, et al. Impaired coronary flow reserve in young patients affected by severe psoriasis. Atherosclerosis. 2012;221(1):113–7.PubMedCrossRefGoogle Scholar
  145. 145.
    Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–70.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–7.PubMedCrossRefGoogle Scholar
  147. 147.
    Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15(1):45–50.PubMedCrossRefGoogle Scholar
  148. 148.
    Wu JJ, Poon KY. Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. J Am Acad Dermatol. 2013;69(4):650–1.PubMedCrossRefGoogle Scholar
  149. 149.
    Piaserico S, Conti A, Console FL, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7. doi: 10.2340/00015555-1719.
  150. 150.
    Huskic´ J, Alendar F. Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis. Bosn J Basic Med Sci. 2007;7(2):103–6.PubMedGoogle Scholar
  151. 151.
    Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40(2):199–205.PubMedGoogle Scholar
  152. 152.
    Ryder KW, Epinette WW, Jay SJ, Ransburg RC, Glick MR. Serum angiotensin converting enzyme activity in patients with psoriasis. Clin Chim Acta. 1985;153(2):143–6.PubMedCrossRefGoogle Scholar
  153. 153.
    Liu T, Han Y, Lu L. Angiotensin-converting enzyme gene polymorphisms and the risk of psoriasis: a meta-analysis. Clin Exp Dermatol. 2013;38(4):352–8. quiz 359PubMedCrossRefGoogle Scholar
  154. 154.
    Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–42. discussion 442–443PubMedCrossRefGoogle Scholar
  155. 155.
    Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med. 2002;346(25):1999–2001.PubMedCrossRefGoogle Scholar
  156. 156.
    Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci. 2011;63(1):1–9.PubMedCrossRefGoogle Scholar
  157. 157.
    Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010;90(1):23–6.PubMedCrossRefGoogle Scholar
  158. 158.
    Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;(1):CD007893.Google Scholar
  159. 159.
    Waqar S, Sarkar PK. Exacerbation of psoriasis with beta-blocker therapy. CMAJ. 2009;181(1–2):60.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    O’Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 2006;5(5):426–32.PubMedGoogle Scholar
  161. 161.
    Wilson PW. Established risk factors and coronary artery disease: the Framingham study. Am J Hypertens. 1994;7(7 Pt 2):7S–12S.PubMedCrossRefGoogle Scholar
  162. 162.
    Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85(6):2025–33.PubMedCrossRefGoogle Scholar
  163. 163.
    Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study. Implications for treatment. Circulation. 1992;85(1):37–45.PubMedCrossRefGoogle Scholar
  164. 164.
    Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore coronary observational long-term study. J Am Coll Cardiol. 1998;31(6):1252–7.PubMedCrossRefGoogle Scholar
  165. 165.
    Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.PubMedCrossRefGoogle Scholar
  166. 166.
    Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis – a double-edged sword. Ann Med. 2008;40(8):606–21.PubMedCrossRefGoogle Scholar
  167. 167.
    Feingold KR, Marshall M, Gulli R, Moser AH, Grunfeld C. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb. 1994;14(11):1866–72.PubMedCrossRefGoogle Scholar
  168. 168.
    Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 1992;52(15):4113–6.PubMedGoogle Scholar
  169. 169.
    Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol. 1985;135(6):3969–71.PubMedGoogle Scholar
  170. 170.
    Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992;41(Suppl 2):97–101.PubMedCrossRefGoogle Scholar
  171. 171.
    Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology. 1993;132(5):2246–53.PubMedCrossRefGoogle Scholar
  172. 172.
    Rashmi R, Rao KSJ, Basavaraj KH. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol. 2009;34(6):658–63.PubMedCrossRefGoogle Scholar
  173. 173.
    Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303(1–2):33–9.PubMedCrossRefGoogle Scholar
  174. 174.
    Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediat Inflamm. 2007;2007:78454.Google Scholar
  175. 175.
    Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013;168(3):486–95.PubMedCrossRefGoogle Scholar
  176. 176.
    Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment. Br J Dermatol. 2013;168(5):984–9.PubMedCrossRefGoogle Scholar
  177. 177.
    Jamnitski A, Levels JH, van den Oever IA, Nurmohamed MT. Highdensity lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol. 2013;40(6):825–30.PubMedCrossRefGoogle Scholar
  178. 178.
    Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol. 2005;32(2):252–5.PubMedGoogle Scholar
  179. 179.
    Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(5):921–3.PubMedGoogle Scholar
  180. 180.
    Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(9):1495–8.PubMedCrossRefGoogle Scholar
  181. 181.
    Mathieu S, Dubost JJ, Tournadre A, Malochet-Guinamand S, Ristori JM, Soubrier M. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine. 2010;77(1):50–2.PubMedCrossRefGoogle Scholar
  182. 182.
    Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-tosevere chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol. 2011;21(6):916–20.PubMedGoogle Scholar
  183. 183.
    Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol. 2006;154(1):83–6. doi: 10.1530/ eje.1.02057.PubMedCrossRefGoogle Scholar
  184. 184.
    Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol. 1989;20(6):1088–93.PubMedCrossRefGoogle Scholar
  185. 185.
    Vahlquist A, Törmä H. Retinoids and keratinization. Current concepts. Int J Dermatol. 1988;27(2):81–95.PubMedCrossRefGoogle Scholar
  186. 186.
    Ellis CN, Kang S, Vinik AI, Grekin RC, Cunningham WJ, Voorhees JJ. Glucose and insulin responses are improved in patients with psoriasis during therapy with etretinate. Arch Dermatol. 1987;123(4):471–5.PubMedCrossRefGoogle Scholar
  187. 187.
    Zech LA, Gross EG, Peck GL, Brewer HB. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. Arch Dermatol. 1983;119(12):987–93.PubMedCrossRefGoogle Scholar
  188. 188.
    Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf. 2001;24(6):443–56.PubMedCrossRefGoogle Scholar
  189. 189.
    Grossman RM, Delaney RJ, Brinton EA, Carter DM, Gottlieb AB. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol. 1991;25(4):648–51.PubMedCrossRefGoogle Scholar
  190. 190.
    Rajpara AN, Goldner R, Gaspari A. Psoriasis: can statins play a dual role? Dermatol Online J. 2010;16(2):2.Google Scholar
  191. 191.
    Hilgendorff A, Muth H, Parviz B, et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003;41(9):397–401.PubMedCrossRefGoogle Scholar
  192. 192.
    Brauchli YB, Jick SS, Meier CR. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol. 2011;65(1):77–83.PubMedCrossRefGoogle Scholar
  193. 193.
    Jacobi TC, Highet A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol. 2003;149(6):1305–6.PubMedCrossRefGoogle Scholar
  194. 194.
    Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol. 2007;57(3):529–31.PubMedCrossRefGoogle Scholar
  195. 195.
    Fisher DA, Elias PM, LeBoit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol. 1988;124(6):854–5.PubMedCrossRefGoogle Scholar
  196. 196.
    Milavec-Puretic´ V, Mance M, Ceovic´ R, Lipozencˇic´ J. Drug induced psoriasis. Acta Dermatovenerol Croat. 2011;19(1):39–42.PubMedGoogle Scholar
  197. 197.
    McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(Suppl 1):S17–29.PubMedGoogle Scholar
  198. 198.
    Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38.PubMedCrossRefGoogle Scholar
  199. 199.
    Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.PubMedCrossRefGoogle Scholar
  200. 200.
    Miele L, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):778–86.PubMedCrossRefGoogle Scholar
  201. 201.
    Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol. 2012;53(3):190–7.PubMedCrossRefGoogle Scholar
  202. 202.
    Gisondi P, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758–64.PubMedCrossRefGoogle Scholar
  203. 203.
    Wenk KS, et al. Psoriasis and nonalcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25:383–91.PubMedCrossRefGoogle Scholar
  204. 204.
    Cassano N, et al. Alcohol, psoriasis, liver disease and anti-psoriasis drugs. Int J Dermatol. 2011;50:1323–31.PubMedCrossRefGoogle Scholar
  205. 205.
    Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312(13):818–22.PubMedCrossRefGoogle Scholar
  206. 206.
    Leonard PA, Clegg DO, Carson CC, Cannon GW, Egger MJ, Ward JR. Low dose pulse methotrexate in rheumatoid arthritis: an 8-year experience with hepatotoxicity. Clin Rheumatol. 1987;6(4):575–82.PubMedCrossRefGoogle Scholar
  207. 207.
    Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009;160(3):622–8.PubMedCrossRefGoogle Scholar
  208. 208.
    van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44(7):1515–24.PubMedCrossRefGoogle Scholar
  209. 209.
    Salonen SH. EUROPSO psoriasis patient survey: first results from 17 990 association members with psoriasis. J Eur Acad Dermatol Venereol. 2003;17(S1):36–46.Google Scholar
  210. 210.
    Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol. 2011;25(7):758–64.PubMedCrossRefGoogle Scholar
  211. 211.
    Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650–9.PubMedCrossRefGoogle Scholar
  212. 212.
    Cole JA, Emerton DP, Mackenzie A, Lawinski CP, Clinch PJ, Weston JDW, et al. Evidence review: ultrasound elastography. Centre for Evidence-Based Purchasing. 2009;CEP08052:1–41.Google Scholar
  213. 213.
    Miller MH, Ferguson MA, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int. 2011;31(4):461–73.PubMedCrossRefGoogle Scholar
  214. 214.
    Boffa MJ, Smith A, Chalmers R, Mitchell D, Rowan B, Warnes TW, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol. 1996;135(4):538–44.PubMedCrossRefGoogle Scholar
  215. 215.
    Rivera R, Vanaclocha F. Nonalcoholic fatty liver disease and psoriasis. Actas Dermotosifiliogr. 2010;101:657–8.CrossRefGoogle Scholar
  216. 216.
    Hannuksela-Svahn A, Pukkala E, Läärä E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol. 2000;114(3):587–90.PubMedCrossRefGoogle Scholar
  217. 217.
    Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993;85(4):307–11.PubMedCrossRefGoogle Scholar
  218. 218.
    Ekström K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003;48(4):963–70.PubMedCrossRefGoogle Scholar
  219. 219.
    Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009;129(11):2604–12.PubMedCrossRefGoogle Scholar
  220. 220.
    Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther. 2010;23(2):174–80.PubMedCrossRefGoogle Scholar
  221. 221.
    Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology. 2010;220(1):38–43.PubMedCrossRefGoogle Scholar
  222. 222.
    Lee MS, Lin RY, Chang YT, Lai MS. The risk of developing nonmelanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int J Dermatol. 2012;51(12):1454–60.PubMedCrossRefGoogle Scholar
  223. 223.
    Pouplard C, et al. Risk of cancer in psoriasis: a systematic review and metaanalysis of epidemiological studies. J Eur Acad Dermatol. 2013;27(Suppl 3):36–46.CrossRefGoogle Scholar
  224. 224.
    Stern RS, PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet a therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553–62.PubMedCrossRefGoogle Scholar
  225. 225.
    Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet a radiation (PUVA). The PUVA follow-up study. N Engl J Med. 1997;336(15):1041–5.PubMedCrossRefGoogle Scholar
  226. 226.
    Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006;142(9):1132–5.PubMedGoogle Scholar
  227. 227.
    Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120(2):211–6.PubMedCrossRefGoogle Scholar
  228. 228.
    Colombo MD, Cassano N, Bellia G, Vena GA. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorld Journal. 2013;2013:805705.PubMedPubMedCentralCrossRefGoogle Scholar
  229. 229.
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85.PubMedCrossRefGoogle Scholar
  230. 230.
    Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data metaanalysis of randomised controlled trials. Ann Rheum Dis. 2009;68(7):1177–83.PubMedCrossRefGoogle Scholar
  231. 231.
    Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposureadjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68(7):1136–45.PubMedCrossRefGoogle Scholar
  232. 232.
    Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adult patients with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–50.PubMedPubMedCentralCrossRefGoogle Scholar
  233. 233.
    Ginsburg IH, Link BG. Psychosocial consequnences of rejection and stigma feelings in psoriasis patients. Int J Dermatol. 1993;32(8):587–91.PubMedCrossRefGoogle Scholar
  234. 234.
    Devrimci-Ozguven H, et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14(4):267–71.PubMedCrossRefGoogle Scholar
  235. 235.
    Esposito M, et al. An Italian study on psoriasis and depression. Dermatology. 2006;212(2):123–7.PubMedCrossRefGoogle Scholar
  236. 236.
    Kilic A, et al. Temperament and character profile of patients with psoriasis. J Eur Acad Dermatol Venereol. 2008;22(5):537–42.PubMedCrossRefGoogle Scholar
  237. 237.
    Sampogna F, et al. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92:299–303.PubMedCrossRefGoogle Scholar
  238. 238.
    Dominguez PL, et al. Depression and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2013;27:1163–7.PubMedCrossRefGoogle Scholar
  239. 239.
    Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29(2):201–17.CrossRefGoogle Scholar
  240. 240.
    Scharloo M, Kaptein AA, Weinman J, Bergman W, Vermeer BJ, Rooijmans HG. Patients’ illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol. 2000;142(5):899–907.PubMedCrossRefGoogle Scholar
  241. 241.
    Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846–50.PubMedCrossRefGoogle Scholar
  242. 242.
    Krueger G, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–4.PubMedGoogle Scholar
  243. 243.
    Gupta MA, Gupta AK. The psoriasis life stress inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75(3):240–3.PubMedGoogle Scholar
  244. 244.
    Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis. 1998;61(6):339–42.PubMedGoogle Scholar
  245. 245.
    Fortune DG, Main CJ, O’Sullivan TM, Griffiths CE. Assessing illnessrelated stress in psoriasis: the psychometric properties of the psoriasis life stress inventory. J Psychosom Res. 1997;42(5):467–75.PubMedCrossRefGoogle Scholar
  246. 246.
    Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146(3):458–65.PubMedCrossRefGoogle Scholar
  247. 247.
    Kastelan D, Kastelan M, Massari LP, Korsic M. Possible association of psoriasis and reduced bone mineral density due to increased TNF-alpha and IL-6 concentrations. Med Hypotheses. 2006;67:1403–5.PubMedCrossRefGoogle Scholar
  248. 248.
    Millard TP, Antoniades L, Evans AV, Smith HR, Spector TD, Barker JN. Bone mine-ral density of patients with chronic plaque psoriasis. Clin Exp Dermatol. 2001;26:446–8.PubMedCrossRefGoogle Scholar
  249. 249.
    Hofbauer LC, Schoppet M, Christ M, Teichmann J, Lange U. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology (Oxford). 2006;45:1218–22.CrossRefGoogle Scholar
  250. 250.
    Attia EA, Khafagy A, Abdel-Raheem S, Fathi S, Saad AA. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. Int J Dermatol. 2011;50:30–5.PubMedCrossRefGoogle Scholar
  251. 251.
    Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther. 2011;13:R16.PubMedPubMedCentralCrossRefGoogle Scholar
  252. 252.
    D’Epiro S, Marocco C, Salvi M, et al. Psoriasis and bone mineral density: implications for long term patients. J Dermatol. 2014;41:783–7.PubMedCrossRefGoogle Scholar
  253. 253.
    Ogdie A, Schwartzman S, Eder L, et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol. 2014;41:2315–22.PubMedCrossRefGoogle Scholar
  254. 254.
    Fraga NA, Oliveira MF, Follador I, Rocha BO, Rêgo VR. Psoriasis and uveitis: a literature review. An Bras Dermatol. 2012;87:877.PubMedPubMedCentralCrossRefGoogle Scholar
  255. 255.
    Oliveira MFSP, Rocha BO, Boeira VLSV, Fraga NAA Follador I, et al. Ophthalmic manifestations in psoriatic patients in a Brazilian referral center. 3rd World Psoriasis & Psoriatic Arthritis Conference 2012, Stockholm. New York, Springer Healthcare, 2012. 2. S24–S25.Google Scholar
  256. 256.
    Dreiher J, et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol. 2008;159(4):956–60.PubMedCrossRefGoogle Scholar
  257. 257.
    Chiang YY, Lin HW. Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2012;26(1):59–65.PubMedCrossRefGoogle Scholar
  258. 258.
    Karaca S, et al. Might psoriasis be a risk factor for obstructive sleep apnea syndrome. Sleep Breath. 2013;17(1):27580.CrossRefGoogle Scholar
  259. 259.
    Papadavid E, et al. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role? J Eur Acad Dermatol Venereol. 2013;27(7):820–6.PubMedCrossRefGoogle Scholar
  260. 260.
    Reynolds OD. Erectile dysfunction in etretinate treatment. Arch Dermatol. 1991;127:425–6.PubMedCrossRefGoogle Scholar
  261. 261.
    Wylie G, Evans CD, Gupta G. Reduced libido and erectile dysfunction: rarely reported side-effects of methotrexate. Clin Exp Dermatol. 2009;34:e234.PubMedCrossRefGoogle Scholar
  262. 262.
    Rossi M, Pellegrino M. Acitretin-associated erectile dysfunction: a case report. Cases J. 2009;2:210.PubMedPubMedCentralCrossRefGoogle Scholar
  263. 263.
    Sheu JJ, Wang KH, Lin HC, Huang CC. Psoriasis is associated with an increased risk of parkinsonism: a population-based 5-year follow-up study. J Am Acad Dermatol. 2013;68:992–9.PubMedCrossRefGoogle Scholar
  264. 264.
    Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol. 2000;25:107–10.PubMedCrossRefGoogle Scholar
  265. 265.
    Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Kärkkäinen P. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ. 1990;300:780–3.PubMedPubMedCentralCrossRefGoogle Scholar
  266. 266.
    Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999;135:1490–3.PubMedCrossRefGoogle Scholar
  267. 267.
    Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61–7.PubMedCrossRefGoogle Scholar
  268. 268.
    Fortes C, Mastroeni S, Leffondré K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580–4.PubMedCrossRefGoogle Scholar
  269. 269.
    Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingård E, Ståhle M. Excessive body. Weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol. 2009;89:492–7.PubMedCrossRefGoogle Scholar
  270. 270.
    Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol. 1993;32:188–90.PubMedCrossRefGoogle Scholar
  271. 271.
    Park B, Lim H, Kim B, Lee W, Kim D, Lee S. Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease. Ann Dermatol. 2009;21(1):60–2.PubMedPubMedCentralCrossRefGoogle Scholar
  272. 272.
    Kimball AB, Wu Y. Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol. 2009;48(11):1147–56.PubMedCrossRefGoogle Scholar
  273. 273.
    Parsi KK, Brezinski EA, Lin TC, Li CS, Armstrong AW. Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists. J Am Acad Dermatol. 2012;67(3):357–62.PubMedCrossRefGoogle Scholar
  274. 274.
    Kimball A, Gladman D, Gelfand J, et al. National Psoriasis Foundation clinical consensus on psoriasis co-morbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–42.PubMedPubMedCentralCrossRefGoogle Scholar
  275. 275.
    El Miedany Y, El Gaafary M, Youssef S, Bahlas S, Almedany S, Ahmed I, Palmer D. Toward electronic health recording: evaluation of electronic patient-reported outcome measures system for remote monitoring of early rheumatoid arthritis. J Rheumatol. 2016;43(12):2106–12.PubMedCrossRefGoogle Scholar
  276. 276.
    El Miedany Y, El Gaafary M, Palmer D. Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study. Rheumatol Int. 2012;32(10):3061–8.PubMedCrossRefGoogle Scholar
  277. 277.
    El Miedany Y, El Gaafary M, Youssef S, Bahlas S, Hegazi M. Psoriatic arthritis comorbidity index: development and validation of a new specific tool for classifying prognostic comorbidity in psoriasis and psoriatic arthritis patients. Rheumatol Orthop Med. 2017;2(2):1–7. doi: 10.15761/ROM.1000117.
  278. 278.
    Basavaraj KH, Navya MA, Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011;50:783–92.PubMedCrossRefGoogle Scholar
  279. 279.
    Duarte GV, Follador I, Cavalheiro CM, Silva TS, Oliveira MF. Psoriasis and obesity: literature review and recommendations for management. An Bras Dermatol. 2010;85:355–60.PubMedCrossRefGoogle Scholar
  280. 280.
    El Miedany Y, El Gaafary M, Sayed S, Palmer D, Ahmed I. Implementing shared decision making in clinical practice: outcomes of a new shared decision making aid for chronic inflammatory arthritis patients. J Pat Care. 2016;2:2–7.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of DermatologyLewisham and Greenwich NHS Trust, Queen Elizabeth HospitalLondonUK
  2. 2.King’s CollegeLondonUK
  3. 3.Rheumatology and Rehabilitation, Ain Shams UniversityCairoEgypt
  4. 4.Department of RheumatologyDarent Valley HospitalDartford, KentUK

Personalised recommendations